Charles F Jr Wagner Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 month, 1 week ago
Charles F Jr Wagner has an estimated net worth of at least $33.3 million*, as of Oct. 29, 2025. They own 37,725 shares of VRTX stock. They have sold 47,360 shares of VRTX stock since 2021, for an estimated $11.7 million.
Charles F Jr Wagner $VRTX SEC Form 4 Insider Trading
Charles F Jr Wagner has filed a total of 43 insider trades in $VRTX since 2021. Their most recent trade was a sale of 7,000 shares, made on Dec 03, 2025. Their largest trade was a sale of 7,000 shares, made on Dec 03, 2025. We estimate that they now own 37,725 shares of $VRTX, worth an estimated $21.6 million.
Insider Trading at $VRTX
There have been a total of 523 insider trades reported at $VRTX since 2021, with 40,000 shares purchased and 1.0 million shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Bastiano Sanna, and Ourania Tatsis. The most recent trade was a sale of 7,000 shares reported by CHARLES F JR WAGNER (EVP, CO & FO), made on Dec 03, 2025.
History of Insider Stock Trades by Charles F Jr Wagner
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
VRTX
|
Sale | 7,000 | Dec 03, 2025 | Dec. 5, 2025, 5:16 p.m. |
VRTX
|
Sale | 7,000 | Dec 03, 2025 | Dec. 5, 2025, 5:16 p.m. |
VRTX
|
Sale | 3,298 | Mar 10, 2025 | March 12, 2025, 4:11 p.m. |
VRTX
|
Sale | 3,250 | Jun 03, 2024 | June 5, 2024, 4:11 p.m. |
VRTX
|
Sale | 3,250 | May 28, 2024 | May 30, 2024, 4:07 p.m. |
VRTX
|
Sale | 3,000 | Jan 02, 2024 | Jan. 4, 2024, 5:17 p.m. |
VRTX
|
Sale | 3,000 | Nov 20, 2023 | Nov. 21, 2023, 5:07 p.m. |
VRTX
|
Sale | 1,768 | Mar 24, 2023 | March 28, 2023, 4:13 p.m. |
VRTX
|
Sale | 16 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 240 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 360 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 240 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 784 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 360 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX
|
Sale | 24 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 361 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 515 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 327 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 30 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 541 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 185 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 27 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 102 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 420 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 1,153 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 715 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 292 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 62 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX
|
Sale | 100 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 20 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 3 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 32 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 48 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 80 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 60 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX
|
Sale | 300 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX
|
Sale | 1,142 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX
|
Sale | 536 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX
|
Sale | 223 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX
|
Sale | 381 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX
|
Sale | 61 | Mar 17, 2022 | March 21, 2022, 4:12 p.m. |
VRTX
|
Sale | 3,110 | Mar 17, 2022 | March 21, 2022, 4:12 p.m. |
VRTX
|
Sale | 2,944 | Feb 02, 2022 | Feb. 2, 2022, 8 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Stuart A Arbuckle, EVP, COO
-
Jeffrey M Leiden, Executive Chairman
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Reshma Kewalramani, CEO & President
-
Joy Liu, SVP, General Counsel
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Carmen Bozic, EVP and CMO
-
David Altshuler, EVP, Chief Scientific Officer
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Jonathan Biller, EVP and Chief Legal Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Amit Sachdev, EVP, Chief Patient Officer
-
Charles F Jr Wagner, EVP, CO & FO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.